Showing results (301-310 of 313) with videos related to

Sort By:
Pageof 32
ESMO Open|March 1, 2022
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU studyN Girard, S Galland-Girodet, V Avrillon, et al.
ESMO Rare Cancers|July 15, 2025
The European Prospective Investigation into Cancer and Nutrition Cohort (EPIC): a gateway to rare cancer epidemiological researchL Fernandez-Cuesta, C Voegele, B Hemon, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
From randomized trials to the clinic: is it time to implement individual lung-cancer screening in clinical practice? A multidisciplinary statement from French experts on behalf of the French intergroup (IFCT) and the groupe d'Oncologie de langue francaise (GOLF)S Couraud, A B Cortot, L Greillier, et al.
ESMO Open|June 4, 2024
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-RA R Filippi, J Bar, C Chouaid, et al.
ESMO Open|April 17, 2021
Combining immunotherapy with an epidrug in squamous cell carcinomas of different locations: rationale and design of the PEVO basket trialE de Guillebon, M Jimenez, L Mazzarella, et al.
Clinical Lung Cancer|August 12, 2025
AFSOS-SFRO Guidelines on Radiation-Induced Lung InjuryO Cravereau, V Bourbonne, L Vaugier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyA Passaro, J Wang, Y Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2018
New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference CenterF Galateau Salle, N Le Stang, A G Nicholson, et al.
ESMO Open|June 15, 2024
Assessment of the current and emerging criteria for the histopathological classification of lung neuroendocrine tumours in the lungNENomics projectÉ Mathian, Y Drouet, A Sexton-Oates, et al.
Pageof 32